Arnold von Eckardstein

Active 1989–2025

224
Papers
30,209
Citations
102
h-index
218
i10-index

Citations

Citations per year for Arnold von Eckardstein1975: 1 citations1976: 1 citations1978: 1 citations1985: 1 citations1987: 1 citations1990: 3 citations1991: 10 citations1992: 9 citations1993: 16 citations1994: 24 citations1995: 33 citations1996: 40 citations1997: 30 citations1998: 55 citations1999: 74 citations2000: 81 citations2001: 89 citations2002: 121 citations2003: 167 citations2004: 160 citations2005: 175 citations2006: 166 citations2007: 158 citations2008: 168 citations2009: 161 citations2010: 177 citations2011: 180 citations2012: 175 citations2013: 235 citations2014: 215 citations2015: 209 citations2016: 147 citations2017: 195 citations2018: 211 citations2019: 774 citations2020: 827 citations2021: 882 citations2022: 740 citations2023: 656 citations2024: 1,124 citations2025: 616 citations2026: 27 citations1977: no citations, so this year is not shown1979–1984: no citations, so these years are not shown1986: no citations, so this year is not shown1988–1989: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,651 citing papers, 21% of this breakdownChina: 994 citing papers, 7.9% of this breakdownGermany: 870 citing papers, 6.9% of this breakdownUnited Kingdom: 813 citing papers, 6.4% of this breakdownItaly: 643 citing papers, 5.1% of this breakdownCanada: 532 citing papers, 4.2% of this breakdownSwitzerland: 506 citing papers, 4% of this breakdownNetherlands: 470 citing papers, 3.7% of this breakdownAustralia: 450 citing papers, 3.6% of this breakdownFrance: 386 citing papers, 3.1% of this breakdownSpain: 374 citing papers, 3% of this breakdownJapan: 283 citing papers, 2.2% of this breakdown
0%21%Other 28.9%

Fields

  • Medicine68.5%
  • Biochemistry, Genetics and Molecular Biology20%
  • Immunology and Microbiology3.6%
  • Neuroscience1.4%
  • Health Professions1.2%
  • Environmental Science1.1%
  • Other4.2%

Topics

  • Lipoproteins and Cardiovascular Health7.2%
  • Diabetes, Cardiovascular Risks, and Lipoproteins6.6%
  • Cholesterol and Lipid Metabolism3.1%
  • Cancer, Lipids, and Metabolism2.4%
  • Atherosclerosis and Cardiovascular Diseases2.4%
  • Sphingolipid Metabolism and Signaling1.7%
  • Other76.6%

Coauthors

All papers

Open in search
  1. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement

    Authors: , , , , , , , , , , , , , , , , , , , , , - European Heart Journal 2022 cited by 1,297

  2. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Stefanie Leuthard, Raminta Kavaliauskaite, Emrush Rexhaj, Hiroki Shibutani, Vera Ruth Mitter, Christoph Kaiser, Manuel Mayr, Franz R. Eberli, Cróchán J. O’Sullivan, Christian Templin, Arnold von Eckardstein, Art Ghandilyan, Ravindra Pawar, Hans Jonker, Thomas M. Hofbauer, Georg Goliasch, Lia E. Bang, Rikke Sørensen, Maria Natalia Tovar Forero, Sophie Degrauwe, Tim ten Cate - JAMA 2022 cited by 589

  3. High-density lipoprotein revisited: biological functions and clinical relevance

    Authors: , , , - European Heart Journal 2022 cited by 370

  4. HDL in the 21st Century: A Multifunctional Roadmap for Future HDL Research

    Authors: , , , , - Circulation 2021 cited by 334

  5. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine

    Authors: , , , , , , , , , , , , , , , , , , , , - European Heart Journal 2016 cited by 835

  6. Apolipoprotein E Induces Antiinflammatory Phenotype in Macrophages

    Authors: , , , , , , , , , , - Arteriosclerosis Thrombosis and Vascular Biology 2011 cited by 368

  7. Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Atherosclerosis 2019 cited by 238

  8. Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement

    Authors: , , , , , , , , , , , , , , , , , , , , , , - The Lancet Diabetes & Endocrinology 2019 cited by 195

  9. Hereditary Sensory Neuropathy Type 1 Is Caused by the Accumulation of Two Neurotoxic Sphingolipids

    Authors: , , , , , , , , , , , - Journal of Biological Chemistry 2010 cited by 378

  10. Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society

    Authors: , , , , , , , , , , , , , , , , , , , , , - Atherosclerosis 2023 cited by 142

  11. Calorie restriction improves metabolic state independently of gut microbiome composition: a randomized dietary intervention trial

    Authors: , , , , , , , , , , , , , , , , , , , , , - Genome Medicine 2022 cited by 57

  12. Skeletal Muscle Disorders: A Noncardiac Source of Cardiac Troponin T

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Tibor Zehntner, Raoul Giger, Thomas Stoll, Hadrien Schöpfer, Fabian Jordan, Michael Carigiet, Nicola Haeni, Vincent Gysin, Michele Sara Gafner, Desiree Wussler, Luca Koechlin, Michael Freese, Christian Ruiz, Olivia Strauch, Tobias Zimmermann, Ivo Strebel, Ulrich A. Walker, Thomas Vogt, Martina Hartmann, Timo Kahles, Paul Hasler, Funda Seidel, Xenia Zavtsyea, Katharina Rentsch, Sandra Mitrovic, Arnold von Eckardstein, Johannes Mair, Michael Schreinlechner, Wijstke Wallimann, Manuel Dietrich, Tania Carrillo Roah, Markus Knoll, Alexander Fuchs, Ellen Bruske, Matthias Munz, Stefan Kunzelmann, Gesa Albert, Tobias Becher, Peter Kastner, Samuel Katsuyuki Shinjo - Circulation 2022 cited by 115

  13. Structure-function relationships of HDL in diabetes and coronary heart disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - JCI Insight 2019 cited by 114

  14. Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM

    Authors: , , , , , , , , , , , , , , , , , , , , , - Clinical Chemistry 2018 cited by 258

  15. Acute aortic dissection: pathogenesis, risk factors and diagnosis

    Authors: , , - Swiss Medical Weekly 2017 cited by 334

  16. Plasma levels of trimethylamine-N-oxide are confounded by impaired kidney function and poor metabolic control

    Authors: , , , , , , , - Atherosclerosis 2015 cited by 219

  17. Abnormal High-Density Lipoprotein Induces Endothelial Dysfunction via Activation of Toll-like Receptor-2

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Immunity 2013 cited by 307

  18. HDL cholesterol: reappraisal of its clinical relevance

    Authors: , , , , , , , , , - Clinical Research in Cardiology 2017 cited by 290

  19. Oral l-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1

    Authors: , , , , , , , , - Journal of Clinical Investigation 2011 cited by 211

  20. The SPTLC3 Subunit of Serine Palmitoyltransferase Generates Short Chain Sphingoid Bases

    Authors: , , , , , , - Journal of Biological Chemistry 2009 cited by 182

  21. Early Diagnosis of Myocardial Infarction With Point-of-Care High-Sensitivity Cardiac Troponin I

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kathrin Meissner, Caroline Kulangara, Petra Hillinger, Eleni Michou, Dayana Flores, Tobias Reichlin, Beatriz López, Carolina Fuenzalida, Esther Rodríguez Adrada, Eva Ganovská, Jens Lohrmann, Jeffrey Huber, Jana Steude, Andreas Buser, Arnold von Eckardstein, Beata Morawiec, Ewa Nowalany-Kozielska, Piotr Muzyk, Franz Bürgler, Nicolas Geigy - Journal of the American College of Cardiology 2020 cited by 161

  22. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2011 cited by 530

  23. FADS3 is a Δ14Z sphingoid base desaturase that contributes to gender differences in the human plasma sphingolipidome

    Authors: , , , , , , , - Journal of Biological Chemistry 2019 cited by 95

  24. Lipoprotein(a) is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: results from the BIOSIGNAL study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - European Heart Journal 2021 cited by 92